Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GCK | P35557 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6054468 | 0.85 | ALDH1A1 (0.44) | LMNAGCKSMN1; SMN2RAB9APOLB | |
| SCHEMBL20165747 | 0.84 | MEN1 (0.51) | KDM4EGCKSMN1; SMN2POLBGAA | |
| SCHEMBL6845283 | 0.84 | GCK (0.41) | KDM4EGCKSMN1; SMN2NPC1RAB9A | |
| SCHEMBL28455691 | 0.80 | AHR (0.39) | GCKALOX5AP | |
| SCHEMBL4061725 | 0.75 | LMNA (0.44) | KDM4ELMNASMN1; SMN2HTTNPC1 | |
| SCHEMBL9764723 | 0.75 | KDM4E (0.45) | KDM4ELMNASMN1; SMN2HTTNPC1 | |
| SCHEMBL9764726 | 0.75 | PTGS1 (0.46) | KDM4ELMNAGCKSMN1; SMN2HTT | |
| SCHEMBL16267806 | 0.74 | CYP19A1 (0.51) | GCKSLC6A4CYP19A1TLR8MAOB | |
| SCHEMBL8803364 | 0.74 | SLC22A12 (0.45) | KDM4ESMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11458038 | 0.74 | CYP19A1 (0.54) | LMNASMN1; SMN2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2019-11-21 | — | — | US | disclosed |
| EP-3541811-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Joint Stock Company "Biocad" (RU) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018092047-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2018-05-24 | — | — | WO | disclosed |
| US-9346827-B2 | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use | AMGEN INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346827-B2 | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use | AMGEN INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-8962859-B2 | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962859-B2 | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8957083-B2 | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957083-B2 | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8921363-B2 | Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors | AMGEN INC. (US) | 2014-12-30 | — | — | US | disclosed |
| WO-2012071279-A1 | SPIRO-AMINO-IMIDAZOLONE AND SPIRO-AMINO-DIHYDRO-PYRIMIDINONE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012019056-A1 | AMINO-ISO-INDOLE, AMINO-AZA-ISO-INDOLE, AMINO-DIHYDROISOQUINOLINE AND AMINO-BENZOXAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012019056-A1 | AMINO-ISO-INDOLE, AMINO-AZA-ISO-INDOLE, AMINO-DIHYDROISOQUINOLINE AND AMINO-BENZOXAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| EP-2328903-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010030954-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | KDM4E 2994/4885LMNA 1131/4885GCK 4557/4885 |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | KDM4E 3745/4885LMNA 796/4885GCK 4396/4885 |
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, ABL1, CNKSR1 | KDM4E 2267/4885LMNA 946/4885GCK 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.